03/11/2026
Amazing results
A proprietary standardised essential oil distilled from Lavandula angustifolia flowers was originally developed in Germany as an oral treatment for anxiety. Its efficacy for this disorder is now supported by a meta-analysis of five randomised placebo-controlled trials involving 1,213 participants, which found significant improvements in anxiety symptoms and health-related quality of life.
Improvements in accompanying depressive symptoms in these anxiety trials, together with experimental evidence of effects on neuroplasticity and neurotransmitter signalling, encouraged researchers to investigate its potential in major depression. Two recent publications now provide such evidence: an eight-week randomised controlled trial establishing the antidepressant efficacy of lavender oil, and a subsequent analysis of this trial examining which specific depressive symptoms improved.
The initial trial publication reported results for a clinical comparison of lavender oil (80 mg once daily administered in an immediate-release soft capsule) with the antidepressant drug sertraline (50 mg/day) and placebo in 498 adults with mild to moderate major depression. A randomised double dummy (two placebos, one for the drug and one for the essential oil) double blind design was used. Clinically important anxiety disorders were excluded, so the trial findings extend beyond just improvement in depressive symptoms if they accompany an anxiety disorder. All trial participants had diagnosed mild or moderate major depression, with baseline MADRS scores (see below) around 23 to 24 out of a maximum of 60. The current depression episode averaged 3.4 months; 43% were first episodes and 57% recurrent.
Depression severity, measured using the Montgomery-Asberg Depression Rating Scale (MADRS), decreased by 12.1 points with lavender oil, 12.6 with sertraline and approximately 10 with placebo. Hence, lavender oil’s additional benefit over placebo was 2.17 points (95% CI 0.58 to 3.76), compared with 2.59 points for sertraline. Response rates were 53.5%, 54.0% and 41.5%, respectively, while remission rates were 44.4%, 45.2% and 32.6%. For lavender oil, this represents approximately 12 additional responders and remitters per 100 patients treated. Daily functioning also improved, with a 2.40-point advantage over placebo on the Sheehan Disability Scale, encompassing work, social life and family responsibilities.
However, patient-reported depression outcomes were less convincing. In the original report, lavender oil did not significantly outperform placebo on the BDI-II or PHQ-9 scales. Both are questionnaires completed by patients to measure depressive symptoms and track changes with treatment. They assess the preceding two weeks.
The subsequent publication then analysed individual MADRS symptoms using the same trial population and results. Lavender oil showed significant advantages over placebo for apparent and reported sadness, concentration difficulties, lassitude and reduced appetite. The largest additional improvements were in lassitude, at approximately 0.40 points, followed by sadness and concentration, at approximately 0.32 to 0.34 points on the individual six-point scales. Effects on inner tension and anhedonia narrowly missed statistical significance, while sleep and pessimistic thoughts showed no clear benefit. This pattern supports a broader antidepressant action, particularly affecting mood, energy and concentration.
This substantial trial also supports the concept that lavender oil has antidepressant efficacy comparable to sertraline in the population studied. However, because the trial was powered for comparisons with placebo, the design lacked a prespecified equivalence margin, so formal statistical equivalence between the drug and the herbal treatment could not be established.
The original trial reported potentially treatment-related adverse events in 32.9% of participants treated with lavender oil, 28.7% with sertraline and 27.4% with placebo. Belching was the most frequent lavender oil event, affecting 16.5%. Overall tolerability was acceptable and the side effects with lavender oil were mild.
This large and substantial trial strengthens the case for a proprietary lavender essential oil as an effective herbal treatment for mild to moderate major depression. With benefits clearly exceeding placebo and closely matching sertraline on the main clinical outcomes, it marks an important advance in the evidence for herbal medicines in mental health.
What makes this trial particularly remarkable is that just 80 mg a day of a lavender essential-oil preparation, composed mainly of relatively simple monoterpenoid molecules such as linalool and linalyl acetate, produced improvements in depression, response and remission closely matching those of sertraline at 50 mg/day (a drug that took hundreds of millions of dollars to develop). It is a striking demonstration that familiar plant chemistry can deliver substantial clinical benefits similar to a sophisticated modern antidepressant, and thereby is a compelling evidence-backed reason to take the therapeutic potential of herbal medicines that much more seriously.
For more information see:
https://www.medscape.com/viewarticle/lavender-oil-cuts-core-symptoms-major-depression-2026a10010v3?ecd=wnl_tp10_daily_261004_MSCPEDIT_etid8754190&uac=48709HJ&impID=8754190
https://pubmed.ncbi.nlm.nih.gov/38558147/
https://pubmed.ncbi.nlm.nih.gov/42550483/
